Higher-risk MDS and AML: How new guidelines are changing diagnosis, classification and management

MDS - Myeloplastic Syndromes - 2023 Best of Hematology ConferenceПодробнее

Use of Molecular Genetic Testing in MDS and MPNПодробнее

The WHO Updated Diagnostic Criteria for MPNПодробнее

Understanding Higher Risk MDS and Transtion to AMLПодробнее

Higher-risk MDS and newly diagnosed AML: What are the latest developments from EHA 2022?Подробнее

Myelodysplastic syndromes - causes, symptoms, diagnosis, treatment, pathologyПодробнее

What is the cause of MDS? #AMLПодробнее

Advances in Treating High Risk MDS and AMLПодробнее

What’s the connection between myelodysplastic syndrome (MDS) and AML-MRC?Подробнее

Differences and similarities between MDS and AML & how this can inform treatment decisionsПодробнее

Resetting Standards in MDSПодробнее

Updates in the diagnosis, risk stratification & treatment of AML: WHO, ICC, and ELN classificationsПодробнее

Understanding the Recent WHO MDS Classification UpdatesПодробнее

Understanding AMLПодробнее

How likely is it that MDS will progress to AML? and how long does it usually take? #AMLПодробнее

Myelodysplastic Syndrome (MDS) - What is the Treatment?Подробнее

How are high risk and low risk MDS defined? #MDSПодробнее

An Approach to Diagnosis and Staging of MDS: From Morphology to GeneticsПодробнее

Implementing MRD in clinical practice for patients with intermediate-risk AMLПодробнее

What Are My Options with High Risk MDS AMLПодробнее

High Risk MDS Treatment StrategiesПодробнее